Navigation Links
Molecular imaging identifies high-risk patients with heart disease
Date:8/10/2010

Reston, Va.A study published in the August Journal of Nuclear Medicine (JNM) finds that molecular imaginga non-invasive imaging procedurecan identify high-risk patients with potentially life-threatening cardiovascular conditions and help physicians determine which patients are best suited for implantable cardioverter defibrillator (ICD) therapy.

"If the molecular imaging techniques are used for appropriate selection of ICD candidates, not only overuse but also underuse of ICD could be avoided and the assessment may be shown to be more cost-effective," said Kimio Nishisato, M.D., a physician in the cardiology division of Muroram City General Hospital, Muroram, Japan, and corresponding author for the study.

According to researchers from Sapporo University, Sapporo, Japan, the study shows that molecular imaging can play an important role in diagnosing and guiding the treatment strategy for arrhythmia, coronary artery disease and heart failure.

"This research holds significant potential for the detection, diagnosis and treatment of many common cardiovascular conditions," said Tomoaki Nakata, M.D., Ph.D., an associate professor at the Sapporo Medical University School of Medicine and director of the Hokkaido Prefectural Esashi Hospital, Japan. "With molecular imaging, physicians can improve patient care by pinpointing the precise location of the disease in order to eliminate the need for invasive medical devices and unnecessary surgical techniques." Nakata adds that molecular imaging can also reduce unnecessary medical costs by better targeting treatment for each individual patient.

In this study, researchers hypothesized that both the impairment of myocardial perfusion and/or cell viability and cardiac sympathetic innervations are responsible for heart arrhythmia and sudden cardiac death. However, there was no established reliable method, including a molecular imaging technique which is highly objective, reproducible and quantitative. The researchers investigated prognostic implications of cardiac pre-synaptic sympathetic function quantified by cardiac MIBG activity and myocyte damage or viability quantified by cardiac tetrofosmin activity in patients treated with prophylactic use of ICD, by correlating with lethal arrhythmic events which would have been documented during a prospective follow-up. Based on these aspects, the study is the first to show the efficacies of the method for more accurate identification of patients at greater risk of lethal arrhythmias and sudden cardiac death (SCD).

"Sudden cardiac death due to lethal arrhythmia represents an important health care problem in many developed countries," said Ichiro Matsunari, M.D., Ph.D., director of the clinical research department at the Medical & Pharmacological Research Center Foundation, Hakui, Japan, and author of an invited perspective also published in the August JNM. "While implantable cardioverter defibrillator therapy is an effective option over anti-arrhythmic medications to prevent SCD, the balance of clinical benefits, efficacy and risks is still a matter of discussion."

Matsunari adds that better, more precise strategies such as the molecular imaging technique used in this study are needed to identify high-risk patients for SCD, who are most likely to benefit from ICD therapy. SCD is often the first manifestation of an underlying diseasebut one that current treatments such as ICD cannot always detect. Molecular imaging helps guide diagnosis and treatment as well as helps avoid unnecessary ICD treatment.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Researchers develop magnetic molecular machines to deliver drugs to unhealthy cells
2. New diagnostic chip able to generate single-cell molecular fingerprints for brain tumors
3. Scientists find unsuspected molecular link between obesity and insulin resistance
4. Study Points to Molecular Origins of Celiac Disease
5. Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes
6. Molecular signatures may aid fight against pediatric liver disease
7. Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes
8. SNMs 2010 Annual Meeting reveals latest developments in molecular imaging and nuclear medicine
9. SNM 2010 image of the year: Molecular imaging shows parathyroid disease in greater detail
10. Molecular Devices Relaunches with HiveMind Marketing
11. Molecular imaging detects recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: